Seeking Alpha

Salix Pharmaceutical's (SLXP +1.4%) moves up after the FDA approves Fulyzaq to relieve symptoms...

Salix Pharmaceutical's (SLXP +1.4%) moves up after the FDA approves Fulyzaq to relieve symptoms of diarrhea in HIV/AIDS patients taking antiretroviral therapy. The drug, which is the first of its kind to relieve diarrhea in AIDS patients and is a common reason why patients discontinue or switch their antiretroviral therapies, is distributed by SLXP under license from Napo Pharmaceuticals.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|